Herein, we summarized the clinical effects of corresponding therapies of EGFR/ALK-TKIs and ICIs, including monotherapy, combination, and sequential therapy, and hopefully, the information provided from this study may be beneficial for the treatment of NSCLC patients now and in the foreseeable future. The gene discussed is ALK; the disease is non-small cell lung carcinoma.